Showing no significant difference in plasma IP-10 levels in samples derived from baseline and at 6 months follow-up.

<p>Showing no significant difference in plasma IP-10 levels in samples derived from baseline and at 6 months follow-up.</p

Baseline characteristics for study patients.

<p>Baseline characteristics for study patients.</p

Linear regression showing correlation between HCV-RNA Concentrations in plasma and DBS samples.

<p>Linear regression showing correlation between HCV-RNA Concentrations in plasma and DBS samples.</p

Median plasma IP-10 concentrations at baseline in relation to genotype, ALT levels, TE-score levels- and dynamics and plasma HCV-RNA concentration.

<p>Median plasma IP-10 concentrations at baseline in relation to genotype, ALT levels, TE-score levels- and dynamics and plasma HCV-RNA concentration.</p

Plasma human immunodeficiency virus 1 RNA and CD4+ T-Cell counts are determinants of virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND cohort study

Background: There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluated the impact of different baseline variables in the RESPOND cohort. Methods:We included treatment-naive participants aged ≥18 who initiated 3-drug ART, in 2014-2020. We assessed the odds of virological suppression (VS) at weeks 48 and 96 using logistic regression. Viral blips, low-level viremia (LLV), residual viremia (RV), and virological failure (VF) rates were assessed using Cox regression. Results: Of 4310 eligible participants, 72% started integrase strand transfer inhibitor (INSTI)-based regimens. At 48 and 96 weeks, 91.0% and 93.3% achieved VS, respectively. At 48 weeks, Kaplan-Meier estimates of rates were 9.6% for viral blips, 2.1% for LLV, 22.2% for RV, and 2.1% for VF. Baseline HIV-1 RNA levels >100 000 copies/mL and CD4+ T-cell counts ≤200/µL were negatively associated with VS at weeks 48 (adjusted odds ratio, 0.51 [95% confidence interval, .39-.68] and .40 [.27-.58], respectively) and 96 and with significantly higher rates of blips, LLV, and RV. CD4+ T-cell counts ≤200/µL were associated with higher risk of VF (adjusted hazard ratio, 3.12 [95% confidence interval, 2.02-4.83]). Results were consistent in those starting INSTIs versus other regimens and those starting dolutegravir versus other INSTIs. Conclusions:Initial high HIV-1 RNA and low CD4+ T-cell counts are associated with lower rates of VS at 48 and 96 weeks and higher rates of viral blips, LLV, and RV. Low baseline CD4+ T-cell counts are associated with higher VF rates. These associations remain with INSTI-based and specifically with dolutegravir-based regimens. These findings suggest that the impact of these baseline determinants is independent of the ART regimen initiated.</p